Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Genentech, Inc.
Yonsei University
Guangdong Provincial People's Hospital
Duke University
Shanghai Pulmonary Hospital, Shanghai, China
Anhui Provincial Cancer Hospital
Sichuan University
Alliance for Clinical Trials in Oncology
TheraOp
Università Vita-Salute San Raffaele
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University Medical Centre Maribor
Fudan University
Fudan University
University Hospital, Essen
Shanghai Pulmonary Hospital, Shanghai, China
GlaxoSmithKline
NYU Langone Health
Shandong Public Health Clinical Center
China Medical University, China
Memorial Sloan Kettering Cancer Center
Innate Pharma
Fudan University
University of Kentucky
Tianjin Medical University Cancer Institute and Hospital
Hunan Province Tumor Hospital
First People's Hospital of Hangzhou
Hunan Province Tumor Hospital
Sun Yat-sen University
Shanghai Pulmonary Hospital, Shanghai, China
Fudan University
Fudan University
Wake Forest University Health Sciences
Hunan Province Tumor Hospital
Henan Cancer Hospital
Second Affiliated Hospital of Xi'an Jiaotong University
Guangzhou University of Traditional Chinese Medicine
Shandong Cancer Hospital and Institute
Fondazione IRCCS Policlinico San Matteo di Pavia
Shanghai Pulmonary Hospital, Shanghai, China
Hunan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
National Cancer Institute, Naples
Intergroupe Francophone de Cancerologie Thoracique
Tianjin Medical University Cancer Institute and Hospital
Sichuan Cancer Hospital and Research Institute
Second Xiangya Hospital of Central South University
Shandong Cancer Hospital and Institute
Immunicom Inc